JMP Securities Maintains Outperform on Enanta Pharma, Lowers Price Target to $23
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Roy Buchanan has maintained an Outperform rating on Enanta Pharma (NASDAQ: ENTA) but has reduced the price target from $42 to $23.
November 21, 2023 | 11:51 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Enanta Pharma's Outperform rating is maintained by JMP Securities, although the price target has been lowered significantly from $42 to $23.
The reduction in price target by JMP Securities is a significant change that suggests a lower expected future stock price for Enanta Pharma. While the Outperform rating indicates a positive view on the stock's potential, the lowered price target may lead to short-term negative sentiment among investors and could result in a decrease in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100